Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
← catalyst calendarSponsored by ACADIA Pharmaceuticals Inc. (industry) · ACAD — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
170estimated
Sites
30
Countries
Canada, France, Germany +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-27 | actual | When the study began enrolling |
| Primary completion | Oct 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2023-12-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hyperphagia in Prader-Willi Syndrome
Interventions
- Drug: Carbetocin — also filed as ACP-101
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from Baseline at Week 12 in caregiver-rated Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score
measured Baseline to Week 12
Publications
- PMID 42486751 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · ACAD's whole pipeline · Catalyst calendar · Every registered study · What changed